Carol L. Shields
NEW ORLEANS — Choroidal melanoma has a high unmet medical need, according to Carol L. Shields, MD, and results of an early-stage study of a light-activated viral nanoparticle lend encouragement that a therapy may be developed to meet that need.
At Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting,
Shields delivered interim results from the phase 1b/2 open-label ascending single and repeat dose clinical trial designed to evaluate the safety of AU-011 (Aura Biosciences) for treatment of small to medium choroidal melanoma.
Choroidal melanoma is a
Uncategorized